期刊文献+

实时定量反转录聚合酶链反应检测患儿急性粒细胞性白血病1-ETO融合基因的临床意义 被引量:1

Clinical Value of Acute Myeloblastic Leukemia 1-ETO Fusion Transcripts in Children with Acute Myeloblastic Leukemia by Using Real-Time Quantitative Reverse Transcriptase Polymerase Chain Reaction
下载PDF
导出
摘要 目的分析实时定量RT-PCR在检测急性粒细胞性白血病(AML)1-ETO融合基因阳性AML微小残留病中的临床意义。方法对2000年1月-2007年1月收治的32例AML1-ETO阳性AML患儿进行实时定量RT-PCR检测。诱导化疗结束后及在巩固化疗阶段每1.5-2.0个月行AML1-ETO融合基因定量检测。使用Kaplan-Meier法分析不同融合基因水平患儿生存率。采用SPSS10.0软件进行统计学分析。结果共32例患儿进行诱导化疗,其中29例(90.625%)达到形态学完全缓解,3例形态学未缓解后放弃。达到分子生物学缓解患儿有更高的无瘤生存率(P=0.0018)。AML1-ETO高拷贝数组生存率低于低拷贝数组(P=0.1080)。诱导缓解化疗结束后AML1-ETO定量结果示〉10^-3组生存率低于定量〈10^-3组生存率(P=0.0230)。化疗6个月时AML1-ETO定量结果示〉10^-3组生存率高于定量〈10^-3组生存率(P=0.0001)。巩固化疗结束时AML1-ETO定量〉10^-5组生存率低于定量〈10^-5组生存率(P=0.0049)。结论定量评估AML1-ETO阳性的小儿AML微小残留病十分重要,有可能对治疗方案的选择提供重要信息。 Objective To analyze the clinical value of minimal residual disease(MRD) of acute myeloblastic leukemia(AML) with AML 1-ETO by using the real-time quantitative reverse transcriptase polymerase chain reaction(RQ-RT-PCR).Methods From Jan.2001 to Jan.2007,the MRD of 32 AML1-ETO-positive AML patients were analyzed by using PQ-RT-PCR.The detection of the AML1-ETO was taken after the induced chemotherapy every 1.5-2.0 months during the consolidation therapy.The survival of different stages in children with AML was analyzed by SPSS 10.0 software and calculated by using Kaplan-Meier analysis.Results Thirty-two patients received the induced chemotherapy and 29 patients with complete remission morphologically,3 patients had no complete remission morphologically and then gave up.Patients with molecular remission were associated with a high probability of survival(P=0.001 8).Patients with high transcript levels at diagnosis had no difference in event free survival with patients with low transcript levels.The quality of molecular response after induction,6 months in the chemotherapy as well as consolidation period,has significant impact on the event free survival(P=0.023,0.000 1,0.004 9).Conclusion The current study demonstrate that quantitative evaluation of AML1-ETO transcript levels is important and may be helpful for therapeutic decisions in future.
出处 《实用儿科临床杂志》 CAS CSCD 北大核心 2008年第15期1160-1161,1211,共3页 Journal of Applied Clinical Pediatrics
关键词 实时定量反转录聚合酶链反应 融合基因 粒细胞白血病 急性 儿童 real-time reverse transcriptase polymerase chain reaction fusion gene acute myeloblastic leukemia child
  • 相关文献

参考文献2

二级参考文献11

  • 1秦亚溱,李金兰,主鸿鹄,阮国瑞,李玲娣,张艳,许兰平,刘代红,黄晓军,陈珊珊,陆道培,刘艳荣.实时定量RT-PCR监测慢性粒细胞白血病患者造血干细胞移植后bcr-abl mRNA水平[J].中华血液学杂志,2006,27(8):511-514. 被引量:19
  • 2Neumann F, Herold C, Hildebrandt B, et al. Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of bcr-abl positive leukemias and molecular monitoring following allogeneic stem cell transplantation. Eur J Haematol, 2003,70 : 1-10.
  • 3Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have bcr-abl kinase domain mutations. Blood, 2004, 104: 2926-2932.
  • 4Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med, 2003, 349: 1423-1432.
  • 5Hughes T, Branford S. Molecular monitoring of bcr-abl as a guide to clinical management in chronic myeloid leukemia. Blood Rev, 2006, 20:29-41.
  • 6Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) -a Europe Against Cancer Program. Leukemia, 2003,17 : 2474-2456.
  • 7Gabert J, Beillard E, van der Velden VH,et al. Standardization and quality control studies of ' real-time ' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia, 2003, 17:2318-2357.
  • 8Matin D, Kaeda J, Szydlo R, et al. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib : patterns of residual leukemia and prognostic factors for cytogenetic relapse. Leukemia, 2005, 19:507-512.
  • 9Asnafi V, Rubio MT, Delabesse E, et al. Prediction of relapse by day 100 bcr-abl quantification after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia, 2006, 20:793-799.
  • 10Grimwade D, Lo Coco F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia, 2002, 16 : 1959-1973.

共引文献191

同被引文献3

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部